Cargando…

Efficacy and Safety of Danshen Compound Tablets in Preventing Thalidomide-Associated Thromboembolism in Patients with Multiple Myeloma: A Multicenter Retrospective Study

BACKGROUND: Currently available antithrombotic prophylaxis is not perfectly reliable in elderly patients. The aim of this retrospective study was to evaluate the efficacy and safety of Compound Danshen Tablet (CDT) in preventing thromboembolism in multiple myeloma (MM) patients treated with thalidom...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Qing-song, Chen, Lin, Mi, Rui-hua, Ai, Hao, Yin, Jun-jie, Liu, Xiao-juan, Wei, Xu-dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2016
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5077292/ https://www.ncbi.nlm.nih.gov/pubmed/27760978 http://dx.doi.org/10.12659/MSM.900575

Ejemplares similares

Effects of Danshen tablets on pharmacokinetics of amlodipine in rats
por: Zhang, Haixia, et al.
Publicado: (2019)

Thalidomide and its analogues in the treatment of Multiple Myeloma
por: Latif, Tahir, et al.
Publicado: (2012)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Anti-hyperlipidemic effects of the compound Danshen tablet: roles of antioxidation, anti-inflammation, anticoagulation, and anti-apoptosis
por: Guo, Haibiao, et al.
Publicado: (2021)

Exploration on Molecular Mechanism of Reversal Effect of Compound Danshen Tablets on Hepatic Fibrosis Based on Network Pharmacology
por: Cao, Minling, et al.
Publicado: (2022)

Retracted: Exploration on Molecular Mechanism of Reversal Effect of Compound Danshen Tablets on Hepatic Fibrosis Based on Network Pharmacology
por: and Biomechanics, Applied Bionics
Publicado: (2023)

Reversible Pulmonary Hypertension Related to Thalidomide Treatment for Multiple Myeloma
por: Villa, Antonio, et al.
Publicado: (2011)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
por: Castro, T.B.M., et al.
Publicado: (2016)

Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
por: Cury, Priscilla Cury de Camargo, et al.
Publicado: (2020)

Thalidomide for the Treatment of Refractory Multiple Myeloma: Association of Plasma Concentrations of Thalidomide and Angiogenic Growth Factors with Clinical Outcome
por: Kakimoto, Tsunayuki, et al.
Publicado: (2002)

Proangiogenesis effects of compound danshen dripping pills in zebrafish
por: Hu, Yang-Xi, et al.
Publicado: (2022)

Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism
por: Sun, Sen, et al.
Publicado: (2018)

Thalidomide Induced Nonspecific Interstitial Pneumonia in Patient with Relapsed Multiple Myeloma
por: Kang, Myung-Hee, et al.
Publicado: (2010)

Acute Pulmonary Toxicity from Thalidomide in a Patient with Multiple Myeloma
por: Khalsa, Satkirin K., et al.
Publicado: (2015)

The Addition of Low-dose Thalidomide to Bortezomib and Dexamethasone for Refractory Multiple Myeloma
por: Hashimoto, Shigeo, et al.
Publicado: (2016)

Clinical efficacy of Thalidomide combined with PAD Regimen in patients with multiple Myeloma
por: Wang, Yu, et al.
Publicado: (2023)

Thalidomide for Patients with β-Thalassemia: A Multicenter Experience
por: Yang, Kun, et al.
Publicado: (2020)

Comparative Effectiveness of Di'ao Xin Xue Kang Capsule and Compound Danshen Tablet in Patients With Symptomatic Chronic Stable Angina
por: Yu, Yanan, et al.
Publicado: (2014)

Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study
por: Spencer, Andrew, et al.
Publicado: (2008)

The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea
por: Kim, Cheolsu, et al.
Publicado: (2015)

Synergism of Chinese Herbal Medicine: Illustrated by Danshen Compound
por: Su, Xuefeng, et al.
Publicado: (2016)

Recommendations on the Clinical Use of Compound Danshen Dripping Pills
Publicado: (2017)

Thalidomide-based Regimens for Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-analysis
por: Lyu, Wen-Wen, et al.
Publicado: (2016)

Nonspecific Interstitial Pneumonitis after Bortezomib and Thalidomide Treatment in a Multiple Myeloma Patient
por: Kang, Wonseok, et al.
Publicado: (2010)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study
por: Garcia, M Kay, et al.
Publicado: (2014)

Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma
por: Iida, Shinsuke, et al.
Publicado: (2018)

A Case of Internal Carotid Artery Thrombosis associated with Thalidomide Administration in Multiple Myeloma
por: Grima, Maria Angela, et al.
Publicado: (2016)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Adverse Effects of Thalidomide Administration, in Patients with Myeloma Multiplex?
por: Svetlana Balkanov, Krstevska, et al.
Publicado: (2014)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

The Efficacy and Safety of Compound Danshen Dripping Pill Combined with Percutaneous Coronary Intervention for Coronary Heart Disease
por: Li, Cailan, et al.
Publicado: (2020)

Compound danshen tablet ameliorated aβ(25-35)-induced spatial memory impairment in mice via rescuing imbalance between cytokines and neurotrophins
por: Teng, Yan, et al.
Publicado: (2014)

Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma
por: Das, Anupam, et al.
Publicado: (2014)

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients
por: Wu, Shenghao, et al.
Publicado: (2015)

Efficacy and Safety of Bortezomib in Multiple Myeloma Patients with Hepatitis B: A Multicenter Retrospective Study
por: Lu, Jin, et al.
Publicado: (2016)

Compound Danshen tablets downregulate amyloid protein precursor mRNA expression in a transgenic cell model of Alzheimer's disease: Effects and a comparison with donepezil☆
por: Qin, Ren’an, et al.
Publicado: (2012)

An evaluation of factors predicting long-term response to thalidomide in 234 patients with relapsed or resistant multiple myeloma
por: Hus, I, et al.
Publicado: (2004)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
por: Azarm, Taleb, et al.
Publicado: (2012)

Acute Exacerbation of Chronic Hepatitis B During Thalidomide Therapy for Multiple Myeloma: A Case Report
por: Bang, Soo-Mee, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_hd4ibvg0rejs3g6pmbfdtaam8v